Dxcover Recognised for Scientific Excellence at ADLM2024

Distinguished Abstract Award to be presented Wednesday July 31 at Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago.

GLASGOW, Scotland & NASHVILLE, Tenn.–(BUSINESS WIRE)–Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA-Dx™) for early detection of solid tumor cancers, will present its latest clinical evidence as a Distinguished Abstract at the Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago July 28 – August 1, 2024.

Dxcover’s abstract entitled “Multi-omic blood test for early detection of cancer and pre-cancer” is one of only 29 submissions the Academy of Diagnostics & Laboratory Medicine Fellows selected for scientific excellence from a pool of more than 775 abstracts accepted for ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo). Winning abstracts will display the Academy blue ribbon during the ADLM 2024 poster sessions.

President and Chief Executive Officer Professor Matthew J. Baker PhD will present the abstract July 31 9:30am – 5:00pm CT in the Poster Hall. “We are honored that our work has been recognized with a Distinguished Abstract Award by the Academy. We will showcase how our novel approach enables highly accurate early cancer and pre-cancer detection to improve patient outcomes. The Dxcover approach provides a low barrier for integration of our multi-omic blood test into existing pathways as the technology is rapid, simple to use, cost-effective and has minimal sample preparation.”

The company is establishing its US operations while collaborating with US clinicians and healthcare sites to demonstrate the Dxcover® PANAROMIC™ platform for early detection capabilities in solid tumor cancers, including advanced adenoma/colorectal, brain, lung, breast, pancreatic, kidney, liver and others. The turn-key workflow of the Drop.Dry.Detect.® platform enables rapid turnaround of accurate cancer detection results within same day of specimen receipt.

Dxcover limited at ADLM2024

About Dxcover Limited.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple solid tumor cancers, when treatment has a better chance to impact outcomes. The company pioneered Multi-Omic Spectral Analysis for the early detection of cancer by infrared spectroscopy and has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers and adenomas. Dxcover is based in Scotland, United Kingdom and recently incorporated in the US.

For further information go to https://www.dxcover.com/science

The post Dxcover Recognised for Scientific Excellence at ADLM2024 first appeared on Dxcover.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top